Vertex Pharmaceuticals (VRTX) Enterprise Value (2009 - 2026)

Vertex Pharmaceuticals' Enterprise Value history runs 18 years deep, the most recent figure standing at -$7.2 billion for Q1 2026.

• On a quarterly basis, Enterprise Value fell 16.86% year-over-year to -$7.2 billion in Q1 2026; TTM through Mar 2026 was -$7.2 billion, a 16.86% decrease from a year earlier, with the FY2025 full-year figure at -$6.6 billion, down 8.05% from the prior year.
• Enterprise Value fell to -$7.2 billion in Q1 2026 per VRTX's latest filing, from -$6.6 billion in the prior quarter.
• Across five years, Enterprise Value topped out at -$5.8 billion in Q2 2024 and bottomed at -$11.9 billion in Q3 2023.
• The 5-year median for Enterprise Value is -$8.2 billion (2022), against an average of -$8.5 billion.
• Across the five-year window, Enterprise Value plunged 43.24% in 2022 and jumped 48.42% in 2024, its largest moves.
• Year by year, Enterprise Value stood at -$10.8 billion in 2022, then fell by 4.08% to -$11.2 billion in 2023, then soared by 45.48% to -$6.1 billion in 2024, then retreated by 8.05% to -$6.6 billion in 2025, then dropped by 9.66% to -$7.2 billion in 2026.
• Per Business Quant, the three latest VRTX Enterprise Value figures stand at -$7.2 billion (Q1 2026), -$6.6 billion (Q4 2025), and -$6.3 billion (Q3 2025).